Journal of Addictive Diseases
October 2, 2018
Valentin Yurievich Skryabin, М.а. Винникова, A. Yu. Nenastieva et al.
27 citations
The paper describes diagnostic criteria, clinical presentation and types of hallucinogen persisting perception disorder (HPPD), as well as current approaches to the treatment of this phenomenon using available scientific sources. Three case reports are also presented to demonstrate different types of this disorder. The first case report describes a 23-year old patient with a previous history of...
Frontiers in Psychology
September 4, 2018
Raphaël Millière, Robin Carhart-Harris, Leor Roseman et al.
402 citations
In recent years, the scientific study of meditation and psychedelic drugs has seen remarkable developments. The increased focus on meditation in cognitive neuroscience has led to a cross-cultural classification of standard meditation styles validated by functional and structural neuroanatomical data. Meanwhile, the renaissance of psychedelic research has shed light on the neurophysiology of...
Science & Justice
August 21, 2018
Jaime Solano, Leonardo Anabalón, Sylvia Figueroa et al.
17 citations
In nature, there are >200 species of fungi with hallucinogenic properties. These fungi are classified as Psilocybe, Gymnopilus, and Panaeolus which contain active principles with hallucinogenic properties such as ibotenic acid, psilocybin, psilocin, or baeocystin. In Chile, fungi seizures are mainly of mature specimens or spores. However, clandestine laboratories have been found that process...
Expert Review of Clinical Pharmacology
August 13, 2018
Rafael G. Dos Santos, José Carlos Bouso, Miguel Ángel Alcázar‐córcoles et al.
231 citations
Mood, anxiety, and substance-use disorders are among the most prevalent psychiatric disorders in the population. Although several pharmacological treatments are available, they are not effective for a significant proportion of patients and are associated with several adverse reactions. Therefore, new treatments should be explored. Recent studies suggest that serotonergic...
ChemBioChem
August 11, 2018
Felix Blei, Janis Fricke, Jonas Wick et al.
31 citations
Abstract Psilocybe mushrooms are best known for their l ‐tryptophan‐derived psychotropic alkaloid psilocybin. Dimethylation of norbaeocystin, the precursor of psilocybin, by the enzyme PsiM is a critical step during the biosynthesis of psilocybin. However, the “magic” mushroom Psilocybe serbica also mono‐ and dimethylates l ‐tryptophan, which is incompatible with the specificity of PsiM. Here,...
Journal of Psychedelic Studies
July 25, 2018
Rafael G. Dos Santos, Scotty Enyart, José Carlos Bouso et al.
18 citations
Aphantasia ("blind imagination") is a poorly described condition with an uncertain etiology, characterized by reduced or lack of voluntary visual imagery. Preliminary evidence in humans suggests that hallucinogenic or psychedelic drugs that act as agonists of cortical 5-HT2A receptors [lysergic acid diethylamide, psilocybin, and dimethyltryptamine (DMT)] enhance visual imagery. Interview and...
ACS Chemical Neuroscience
July 12, 2018
Lee E. Dunlap, Anne M. Andrews, David E. Olson
105 citations
Better known as "ecstasy", 3,4-methylenedioxymethamphetamine (MDMA) is a small molecule that has played a prominent role in defining the ethos of today's teenagers and young adults, much like lysergic acid diethylamide (LSD) did in the 1960s. Though MDMA possesses structural similarities to compounds like amphetamine and mescaline, it produces subjective effects that are unlike any of the...
July 9, 2018
Chu Hsien Lim, Brian D Kangas, Jack Bergman
1 citation
Cancer patients experience a higher rate of depression and anxiety which can result in negative healthcare outcomes. With the limited treatment options available, there has been an interest in using psychedelics such as psilocybin to manage such complications. Recently, two studies demonstrated the
Frontiers in Pharmacology
July 5, 2018
Eduardo Ekman Schenberg
242 citations
Mental disorders are rising while development of novel psychiatric medications is declining. This stall in innovation has also been linked with intense debates on the current diagnostics and explanations for mental disorders, together constituting a paradigmatic crisis. A radical innovation is psychedelic-assisted psychotherapy (PAP): professionally supervised use of ketamine, MDMA, psilocybin,...
International Review of Psychiatry
July 4, 2018
Thomas W. Flanagan, Charles D. Nichols
263 citations
Serotonin (5-hydroxytryptamine, 5-HT)2A receptor agonists have recently emerged as promising new treatment options for a variety of disorders. The recent success of these agonists, also known as psychedelics, like psilocybin for the treatment of anxiety, depression, obsessive-compulsive disorder (OCD), and addiction, has ushered in a renaissance in the way these compounds are perceived in the...